Company intelligence / Profile preview

Photys Therapeutics

Cambridge, Massachusetts, United Statesphotys.com ↗

Ownership: Private
Employees: ~11
Development stage: Phase 1

Overview

Photys has presented preclinical data on its bifunctional molecules driving apoptosis in cancer models and has licensed a Phase I-ready IRAK4 degrader. No clinical results have been published yet; programs are primarily in preclinical or IND-enabling stages.

Therapeutic areas: CardiovascularMetabolic DisordersImmunologyOncologyRare Diseases
Modalities: Bifunctional small molecules (including PHICS, PROTACs, tPRIME)
Industry: Biotech

Drug pipeline

4 assets

PTX-201

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Novo Nordisk – research collaboration for cardiometabolic disease using PHICS technologyPolymed – exclusive license agreement for Phase I-ready IRAK4 degrader

Beyond the preview

Go deeper on Photys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photys Therapeutics.

Explore the full profile